Investment in HIV Prevention Research & Development

Funding in 2016

Investment priorities: Funding innovation in a challenging global health landscape

Trends in HIV Prevention Research and Development

In 2016, reported funding for HIV prevention R&D decreased by 3.5% from US $1.20 billion in 2015 to US$1.17 billion. This signals the lowest annual investment in HIV prevention R&D in more than a decade.

Selected Report Key Findings

Intensifying trend towards a small number of large investors

The call for a more diverse base of funders in the prevention R&D landscape is not a new one, but recent trends display greater polarization and a more extreme funding imbalance. Simply put, for every dollar spent on HIV prevention R&D in 2016, 88 cents came from just two donors.

Diminished funding beyond the US public sector

In 2015, public-sector investments outside the US had amounted to US$119 million, however this number fell to US$71 million in 2016. Compared to the previous year, Australia, Brazil, India and Japan reduced funding by 42 percent, 50 percent, 74 percent and 42 percent, respectively.